Finally, new data about the use of miRNAs as a drug in pre-clinical studies and additional molecular information regarding GLP1-mediated miRNAs regulation may generate a useful strategy in the innovative field of miRNAs therapy to treat metabolic diseases. This evidence concerns the gene GLP1R and Other metabolic disease.